ea0044ep97 | (1) | SFEBES2016
Pariani Nadia
, Willis Mark
, Muller Ilaria
, Healy Sarah
, Nasser Taha
, Jones Joanne
, Chatterjee V. Krishna K.
, Dayan Colin
, Robertson Neil
, Coles Alasdair
, Moran Carla
Alemtuzumab, a highly effective, newly-licensed, treatment for multiple sclerosis (MS), is notably associated with GravesÂ’ disease (GD), which reportedly has an indolent course.Methods: Case record review of patients who developed thyroid dysfunction (TD) after alemtuzumab treatment in Cambridge & Cardiff, to determine type, frequency and course of TD.Results: 41.8% (104/249; 81F, 23M) of alemtuzumab-treated patients devel...